Charles River to Acquire Cell Therapy Provider HemaCare for $380 MBy
Charles River Laboratories, a contract research organization, has agreed to acquire HemaCare, a producer of human-derived cellular products for cell therapy, for approximately $380 million. The proposed purchase price equates to $25.40 per HemaCare share.
HemaCare supplies biomaterials, including a wide range of human primary cell types, as well as cell processing services to support the discovery, development, and manufacture of cell therapies, including allogeneic (donor-derived cells) and autologous (patient-derived cells) programs. The acquisition adds to Charles River’s portfolio of early-stage research and manufacturing support services.
The transaction has been approved by the Board of Directors of both Charles River and HemaCare, and certain HemaCare directors, officers, and shareholders, which collectively hold more than 50% of HemaCare’s outstanding shares, have approved the transaction by written consent. The acquisition is expected to close early in the first quarter of 2020, subject to receipt of certain regulatory approvals and other customary closing conditions. Following closing, HemaCare will be reported as part of Charles River’s Research Models and Services segment.
Source: Charles River Laboratories, HemaCare